Dr Lal PathLabs

November 7, 2020

National Stock Exchange of India
Limited Exchange Plaza,
Plot No. C/1, G Block,
Bandra Kurla Complex Bandra (E)
Mumbai – 400 051.

Bombay Stock Exchange Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai- 400001

Subject: Newspaper Publication(s)

Ref: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 ("Listing Regulations")

Dear Sir/Madam,

Pursuant to the Regulation 30 of SEBI Listing Regulations, Please find attached copies of newspaper advertisement of Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2020, published in Financial Express and Jansatta on November 7, 2020.

We request you to please take the same on record.

Thanking You,

Yours Faithfully,

For Dr. Lal PathLabs Limited

Dr. Lal PathLabs Limited

Rajat Kalra
Company Secretary and Legal Head

Encl: As above

Dr Lal PathLabs

Dr. Lal PathLabs Limited

CIN: L74899DL1995PLC065388
Regd. Office: Block E, Sector-18, Rohini, New Delhi-110085
Corporate Office: 12th Floor, Tower B, SAS Tower, Medicity, Sector-38, Gurugram-122001, Haryana
Tel.: +91-124-3016500; **Fax:** +91-124-4234468; **Website:** www.lalpathlabs.com; **Email:** cs@lalpathlabs.com

Extract of Consolidated Unaudited Financial Results for the quarter & half year ended 30 September, 2020

(₹ in million, except as stated)

S. No.	Particulars	3 months ended 30 September, 2020 (Unaudited)	Half year ended 30 September, 2020 (Unaudited)	Corresponding 3 months ended 30 September, 2019 (Unaudited)
1	Total Income from Operations	4,448	7,222	3,804
2	Net Profit for the period before Tax and Exceptional items#	1,166	1,547	1,023
3	Net Profit for the period before Tax and after Exceptional items#	1,166	1,547	1,023
4	Net Profit for the period after Tax and after Exceptional items#	871	1,155	810
5	Total Comprehensive Income for the period after Tax#	880	1,155	816
6	Paid-up Equity Share Capital (face value of ₹ 10/- per share)	833	833	833
7	Earnings Per Share (of ₹ 10/- each) (not annualised)			
	(a) Basic (In ₹)	10.34	13.79	9.77
	(b) Diluted (In ₹)	10.31	13.75	9.75

#Before non-controlling Interest

Notes:

i. Key numbers of the Standalone Results are as under:

(₹ in million, except as stated)

S. No.	Particulars	3 months ended 30 September, 2020 (Unaudited)	Half year ended 30 September, 2020 (Unaudited)	Corresponding 3 months ended 30 September, 2019 (Unaudited)
1	Total Income from Operations	4,168	6,829	3,674
2	Profit for the period before Tax	1,068	1,453	998
3	Profit for the period after Tax	799	1,087	795
4	Total Comprehensive Income	809	1,088	802

ii. The above results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 6 November, 2020.

iii. The Board of Directors, which has been identified as being the Chief Operating Decision Maker (CODM), evaluates the Group's performance and allocates resources based on the analysis of the various performance indicators of the Group as a single unit. Therefore, there is no reportable segment for the Group, in accordance with the requirements of Indian Accounting Standard 108 - 'Operating Segments', prescribed under Section 133 of the Companies Act, 2013.

iv. The above is an extract of the detailed format of quarterly and six months financial results, as per Ind AS filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. The full Financial Results of the quarter and half year ended are available on the Stock Exchange websites (www.bseindia.com and www.nseindia.com) and the Company's website (www.lalpathlabs.com).

For and on behalf of the Board of Directors of
Dr. Lal PathLabs Limited

Place: Gurugram
Date: 6 November, 2020

(Hony) Brig. Dr. Arvind Lal
Executive Chairman

Dr Lal Q2 UFR Ad
Jansatta
07th November 2020
Page 10

Dr Lal PathLabs

Dr. Lal PathLabs Limited

CIN: L74899DL1995PLC065388
Regd. Office: Block E, Sector-18, Rohini, New Delhi-110085
Corporate Office: 12th Floor, Tower B, SAS Tower, Medicity, Sector-38, Gurugram-122001, Haryana
Tel.: +91-124-3016500; **Fax:** +91-124-4234468; **Website:** www.lalpathlabs.com; **Email:** cs@lalpathlabs.com

Extract of Consolidated Unaudited Financial Results for the quarter & half year ended 30 September, 2020

(₹ in million, except as stated)

S. No.	Particulars	3 months ended 30 September, 2020 (Unaudited)	Half year ended 30 September, 2020 (Unaudited)	Corresponding 3 months ended 30 September, 2019 (Unaudited)
1	Total Income from Operations	4,448	7,222	3,804
2	Net Profit for the period before Tax and Exceptional items#	1,166	1,547	1,023
3	Net Profit for the period before Tax and after Exceptional items#	1,166	1,547	1,023
4	Net Profit for the period after Tax and after Exceptional items#	871	1,155	810
5	Total Comprehensive Income for the period after Tax#	880	1,155	816
6	Paid-up Equity Share Capital (face value of ₹ 10/- per share)	833	833	833
7	Earnings Per Share (of ₹ 10/- each) (not annualised)			
	(a) Basic (In ₹)	10.34	13.79	9.77
	(b) Diluted (In ₹)	10.31	13.75	9.75

#Before non-controlling Interest

Notes:

i. Key numbers of the Standalone Results are as under:

(₹ in million, except as stated)

S. No.	Particulars	3 months ended 30 September, 2020 (Unaudited)	Half year ended 30 September, 2020 (Unaudited)	Corresponding 3 months ended 30 September, 2019 (Unaudited)
1	Total Income from Operations	4,168	6,829	3,674
2	Profit for the period before Tax	1,068	1,453	998
3	Profit for the period after Tax	799	1,087	795
4	Total Comprehensive Income	809	1,088	802

ii. The above results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 6 November, 2020.

iii. The Board of Directors, which has been identified as being the Chief Operating Decision Maker (CODM), evaluates the Group's performance and allocates resources based on the analysis of the various performance indicators of the Group as a single unit. Therefore, there is no reportable segment for the Group, in accordance with the requirements of Indian Accounting Standard 108 - 'Operating Segments', prescribed under Section 133 of the Companies Act, 2013.

iv. The above is an extract of the detailed format of quarterly and six months financial results, as per Ind AS filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. The full Financial Results of the quarter and half year ended are available on the Stock Exchange websites (www.bseindia.com and www.nseindia.com) and the Company's website (www.lalpathlabs.com).

For and on behalf of the Board of Directors of
Dr. Lal PathLabs Limited

Place: Gurugram
Date: 6 November, 2020

(Hony) Brig. Dr. Arvind Lal
Executive Chairman